Insight Molecular Diagnostics Inc.
DE ˙ MUN ˙ US68235C2061
SecurityDE:7OC0 / Insight Molecular Diagnostics Inc.
InstitutionVanguard Group Inc
Latest Disclosed Ownership526,675 shares
Latest Disclosed Value $ 3,950,064
Vanguard Group Inc reports 8.21% increase in ownership of 7OC0 / Insight Molecular Diagnostics Inc.

On January 29, 2026 - Vanguard Group Inc filed a 13F-HR form disclosing ownership of 526,675 shares of Insight Molecular Diagnostics Inc. (DE:7OC0) valued at $3,950,064 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 7, 2025 disclosing 486,738 shares of Insight Molecular Diagnostics Inc.. This represents a change in shares of 8.21% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-01-29 2025-12-31 13F INSIGHT MOLECULAR DIA COM NEW 68235C206 526,675 39,937 8.21 3,950 144.58 0.0001
2025-11-07 2025-09-30 13F INSIGHT MOLECULAR DIA COM NEW 68235C206 486,738 2,967 0.61 1,616 10.62 0.0000
2025-08-11 2025-06-30 13F INSIGHT MOLECULAR DIA COM NEW 68235C206 483,771 218,314 82.24 1,461 79.80 0.0000
2025-05-09 2025-03-31 13F ONCOCYTE COM NEW 68235C206 265,457 23,251 9.60 812 40.97 0.0000
2025-02-11 2024-12-31 13F ONCOCYTE COM NEW 68235C206 242,206 -3,182 -1.30 576 -17.60 0.0000
2024-11-13 2024-09-30 13F ONCOCYTE COM NEW 68235C206 245,388 899 0.37 699 -3.05 0.0000
2024-08-13 2024-06-30 13F ONCOCYTE COM NEW 68235C206 244,489 -3,384 -1.37 721 -0.69 0.0000
2024-05-10 2024-03-31 13F ONCOCYTE COM NEW 68235C206 247,873 0 0.00 726 17.29 0.0000
2024-03-11 2023-12-31 13F/A-1 ONCOCYTE COM NEW 68235C206 247,873 7,784 3.24 620 -17.36 0.0000
2024-02-14 2023-12-31 13F ONCOCYTE COM NEW 68235C206 247,873 7,784 620 0.0000
2023-12-18 2023-09-30 13F/A-1 ONCOCYTE COM NEW 68235C206 240,089 240,089 749 0.0000
2023-11-14 2023-09-30 13F ONCOCYTE COM NEW 68235C206 240,089 240,089 749 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.